Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance and Biotransformation of [14C]HSK31679 in Healthy Male Chinese Subjects
NCT06258746Phase 1Active, not recruiting
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
- Start
- Dec 2023
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HSK31679 in Nonalcoholic steatohepatitis (NASH), sponsored by Haisco Pharmaceutical Group Co., Ltd. Primary endpoint: Mass balance recovery. Started Dec 2023; status: active, not recruiting.
02
Drugs
HSK31679
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT06258746.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06258746.